[{"orgOrder":0,"company":"CorMedix","sponsor":"RBC Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Public Offering","leadProduct":"Taurolidine","moa":"||Cell wall","graph1":"Nephrology","graph2":"Phase IV","graph3":"CorMedix","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"CorMedix \/ RBC Capital Markets","highestDevelopmentStatusID":"11","companyTruncated":"CorMedix \/ RBC Capital Markets"},{"orgOrder":0,"company":"Comprehensive Research Associates","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Phase IV","graph3":"Comprehensive Research Associates","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Comprehensive Research Associates \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Comprehensive Research Associates \/ Inapplicable"},{"orgOrder":0,"company":"University Medical Center Groningen","sponsor":"Amsterdam University Medical Center | Frisius Medisch Centrum | Isala | CSL Vifor | Dutch Kidney Foundation | Health Holland","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Phase IV","graph3":"University Medical Center Groningen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Medical Center Groningen \/ Amsterdam University Medical Center | Frisius Medisch Centrum | Isala | CSL Vifor | Dutch Kidney Foundation | Health Holland","highestDevelopmentStatusID":"11","companyTruncated":"University Medical Center Groningen \/ Amsterdam University Medical Center | Frisius Medisch Centrum | Isala | CSL Vifor | Dutch Kidney Foundation | Health Holland"},{"orgOrder":0,"company":"USRC Kidney Research","sponsor":"Akebia Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ferric Citrate","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase IV","graph3":"USRC Kidney Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"USRC Kidney Research \/ Akebia Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"USRC Kidney Research \/ Akebia Therapeutics"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Desidustat","moa":"enzyme inhibitors: hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors","graph1":"Nephrology","graph2":"Phase IV","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"NephroNet, Inc.","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Zirconium Cyclosilicate","moa":"Potassium","graph1":"Nephrology","graph2":"Phase IV","graph3":"NephroNet, Inc.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"NephroNet, Inc. \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"NephroNet, Inc. \/ AstraZeneca"},{"orgOrder":0,"company":"Amsterdam UMC","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nephrology","graph2":"Phase IV","graph3":"Amsterdam UMC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amsterdam UMC \/ ZonMw","highestDevelopmentStatusID":"11","companyTruncated":"Amsterdam UMC \/ ZonMw"},{"orgOrder":0,"company":"Washington D.C. VA Medical Center","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nephrology","graph2":"Phase IV","graph3":"Washington D.C. VA Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington D.C. VA Medical Center \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"11","companyTruncated":"Washington D.C. VA Medical Center \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"The First Affiliated Hospital of Dalian Medical University","sponsor":"Huazhong University of Science and Technology | LinkDoc Technology","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Huaiqihuang","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase IV","graph3":"The First Affiliated Hospital of Dalian Medical University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Granules","sponsorNew":"The First Affiliated Hospital of Dalian Medical University \/ Huazhong University of Science and Technology | LinkDoc Technology","highestDevelopmentStatusID":"11","companyTruncated":"The First Affiliated Hospital of Dalian Medical University \/ Huazhong University of Science and Technology | LinkDoc Technology"},{"orgOrder":0,"company":"Jemincare","sponsor":"Shanghai 6th People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Jinshuibao","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase IV","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jemincare \/ Shanghai 6th People's Hospital","highestDevelopmentStatusID":"11","companyTruncated":"Jemincare \/ Shanghai 6th People's Hospital"},{"orgOrder":0,"company":"Jianhua Zhou","sponsor":"LinkDoc Technology","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Huaiqihuang","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase IV","graph3":"Jianhua Zhou","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Jianhua Zhou \/ LinkDoc Technology","highestDevelopmentStatusID":"11","companyTruncated":"Jianhua Zhou \/ LinkDoc Technology"},{"orgOrder":0,"company":"Chinese PLA General Hospital","sponsor":"LinkDoc Technology | Huazhong University of Science and Technology","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Trametes Robiniophila Murr Extract","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase IV","graph3":"Chinese PLA General Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Chinese PLA General Hospital \/ LinkDoc Technology | Huazhong University of Science and Technology","highestDevelopmentStatusID":"11","companyTruncated":"Chinese PLA General Hospital \/ LinkDoc Technology | Huazhong University of Science and Technology"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Medical College of Wisconsin","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Human Papillomavirus 9-valent Vaccine, Recombinant","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase IV","graph3":"Medical College of Wisconsin","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Medical College of Wisconsin \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Medical College of Wisconsin \/ Merck & Co"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Evolocumab","moa":"Subtilisin\/kexin type 9","graph1":"Nephrology","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NYU Langone Health \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Inapplicable"},{"orgOrder":0,"company":"The Methodist Hospital Research Institute","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase IV","graph3":"The Methodist Hospital Research Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"The Methodist Hospital Research Institute \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"The Methodist Hospital Research Institute \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Loyola University","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase IV","graph3":"Loyola University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Loyola University \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Loyola University \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Western University, Canada","sponsor":"ICES | Academic Medical Organization of Southwestern Ontario | Western University | Kidney Foundation of Canada","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Nephrology","graph2":"Phase IV","graph3":"Western University, Canada","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Western University, Canada \/ ICES | Academic Medical Organization of Southwestern Ontario | Western University | Kidney Foundation of Canada","highestDevelopmentStatusID":"11","companyTruncated":"Western University, Canada \/ ICES | Academic Medical Organization of Southwestern Ontario | Western University | Kidney Foundation of Canada"},{"orgOrder":0,"company":"National Healthcare Group, Singapore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Urokinase","moa":"Urokinase-type plasminogen activator","graph1":"Nephrology","graph2":"Phase IV","graph3":"National Healthcare Group, Singapore","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Catheter","sponsorNew":"National Healthcare Group, Singapore \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"National Healthcare Group, Singapore \/ Inapplicable"},{"orgOrder":0,"company":"NephroNet, Inc.","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Corticotropin","moa":"Melanocortin receptor 2","graph1":"Nephrology","graph2":"Phase IV","graph3":"NephroNet, Inc.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Solution","sponsorNew":"NephroNet, Inc. \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"NephroNet, Inc. \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tenapanor","moa":"Sodium\/hydrogen exchanger 3","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Nephrology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Insert","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ferric Pyrophosphate Citrate","moa":"\nFe","graph1":"Nephrology","graph2":"Phase IV","graph3":"Rockwell Medical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rockwell Medical \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Rockwell Medical \/ Inapplicable"},{"orgOrder":0,"company":"Alfredo Di Leo","sponsor":"Alfasigma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Macrogol","moa":"Homeostasis","graph1":"Nephrology","graph2":"Phase IV","graph3":"Alfredo Di Leo","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alfredo Di Leo \/ Alfasigma","highestDevelopmentStatusID":"11","companyTruncated":"Alfredo Di Leo \/ Alfasigma"},{"orgOrder":0,"company":"The Central Hospital of Lishui City","sponsor":"Jiangsu Hengrui Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Gadoteric Acid Meglumine","moa":"Gadolinium (MRI contrast)","graph1":"Nephrology","graph2":"Phase IV","graph3":"The Central Hospital of Lishui City","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Central Hospital of Lishui City \/ Jiangsu Hengrui Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"The Central Hospital of Lishui City \/ Jiangsu Hengrui Pharmaceutical"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Dalim BioTech","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SOUTH KOREA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Vitamin D receptor","graph1":"Nephrology","graph2":"Phase IV","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Dalim BioTech","highestDevelopmentStatusID":"11","companyTruncated":"Seoul National University Hospital \/ Dalim BioTech"},{"orgOrder":0,"company":"Albert Einstein Healthcare Network","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nephrology","graph2":"Phase IV","graph3":"Albert Einstein Healthcare Network","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Albert Einstein Healthcare Network \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Albert Einstein Healthcare Network \/ Inapplicable"},{"orgOrder":0,"company":"Yale University","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nephrology","graph2":"Phase IV","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yale University \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"11","companyTruncated":"Yale University \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"VA Office of Research and Development","sponsor":"Iowa City VA Health Care System | VA Pittsburgh Healthcare System | VA Tennessee Valley Health Care System | VA Hines Health Care","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nephrology","graph2":"Phase IV","graph3":"VA Office of Research and Development","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VA Office of Research and Development \/ Iowa City VA Health Care System | VA Pittsburgh Healthcare System | VA Tennessee Valley Health Care System | VA Hines Health Care","highestDevelopmentStatusID":"11","companyTruncated":"VA Office of Research and Development \/ Iowa City VA Health Care System | VA Pittsburgh Healthcare System | VA Tennessee Valley Health Care System | VA Hines Health Care"},{"orgOrder":0,"company":"Anemia Working Group Romania","sponsor":"Sf Ioan Emergency Clinical Hospital, Nephrology and Dialysis Department, Bucharest, Romania | Dr Carol Davila Teaching Hospital of Nephrology Bucharest | Carol Davila University of Medicine and Pharmacy","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nephrology","graph2":"Phase IV","graph3":"Anemia Working Group Romania","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anemia Working Group Romania \/ Sf Ioan Emergency Clinical Hospital, Nephrology and Dialysis Department, Bucharest, Romania | Dr Carol Davila Teaching Hospital of Nephrology Bucharest | Carol Davila University of Medicine and Pharmacy","highestDevelopmentStatusID":"11","companyTruncated":"Anemia Working Group Romania \/ Sf Ioan Emergency Clinical Hospital, Nephrology and Dialysis Department, Bucharest, Romania | Dr Carol Davila Teaching Hospital of Nephrology Bucharest | Carol Davila University of Medicine and Pharmacy"},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sodium Zirconium Cyclosilicate","moa":"Potassium","graph1":"Nephrology","graph2":"Phase IV","graph3":"Leiden University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leiden University Medical Center \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"Leiden University Medical Center \/ AstraZeneca"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Telmisartan","moa":"Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chong Kun Dang Pharm \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Inapplicable"},{"orgOrder":0,"company":"Chengdu Qingshan Likang Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Amino acid metabolism","graph1":"Nephrology","graph2":"Phase IV","graph3":"Chengdu Qingshan Likang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Chengdu Qingshan Likang Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Chengdu Qingshan Likang Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Zhongshan Hospital","sponsor":"SHENZHEN SALUBRIS PHARMACEUTICALS","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Enadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Phase IV","graph3":"Shanghai Zhongshan Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Zhongshan Hospital \/ SHENZHEN SALUBRIS PHARMACEUTICALS","highestDevelopmentStatusID":"11","companyTruncated":"Shanghai Zhongshan Hospital \/ SHENZHEN SALUBRIS PHARMACEUTICALS"},{"orgOrder":0,"company":"The First Affiliated Hospital of Dalian Medical University","sponsor":"Hansoh Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Pegmolesatide","moa":"Erythropoietin receptor","graph1":"Nephrology","graph2":"Phase IV","graph3":"The First Affiliated Hospital of Dalian Medical University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"The First Affiliated Hospital of Dalian Medical University \/ Hansoh Pharma","highestDevelopmentStatusID":"11","companyTruncated":"The First Affiliated Hospital of Dalian Medical University \/ Hansoh Pharma"},{"orgOrder":0,"company":"First Affiliated Hospital of Wannan Medical College","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Henagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nephrology","graph2":"Phase IV","graph3":"First Affiliated Hospital of Wannan Medical College","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"First Affiliated Hospital of Wannan Medical College \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"11","companyTruncated":"First Affiliated Hospital of Wannan Medical College \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Centre Hospitalier Universitaire de Nice","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Nephrology","graph2":"Phase IV","graph3":"Centre Hospitalier Universitaire de Nice","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Hospitalier Universitaire de Nice \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"11","companyTruncated":"Centre Hospitalier Universitaire de Nice \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Enarodustat","moa":"Egl nine homolog 1","graph1":"Nephrology","graph2":"Phase IV","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Undisclosed"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nephrology","graph2":"Phase IV","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unity Health Toronto \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Unity Health Toronto \/ Undisclosed"},{"orgOrder":0,"company":"Chinese PLA General Hospital","sponsor":"Hansoh Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Pegmolesatide","moa":"Erythropoietin receptor","graph1":"Nephrology","graph2":"Phase IV","graph3":"Chinese PLA General Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chinese PLA General Hospital \/ Hansoh Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Chinese PLA General Hospital \/ Hansoh Pharma"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Details :
Enarodustat is a Other Small Molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Anemia-associated with Renal Insufficiency, Chronic.
Details :
Empagliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Renal Insufficiency, Chronic.
Details :
Pegmolesatide is a Protein drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Kidney Failure, Chronic.
Details :
Henagliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Renal Insufficiency, Chronic.
Details :
Semaglutide is a Peptide drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Renal Insufficiency, Chronic.
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
